{"entity":{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","aka":[],"tldr":"A phase 2 trial of Medium dose for 15-HPV vaccine in advanced solid tumours, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.","summary":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years is a phase 2 interventional study registered as NCT06756269 by Shanghai Bovax Biotechnology Co., Ltd., with 330 participants planned, started 2025-01-15 and due to reach its primary completion in 2025-10-30. Interventions recorded: Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo and 9-HPV vaccine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06756269","url":"https://clinicaltrials.gov/study/NCT06756269"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shanghai-bovax-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06756269","phase":"2","setting":"A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","participation":[{"nct":"NCT06756269","source":"https://clinicaltrials.gov/study/NCT06756269","fetchedAt":"2026-10-07T16:55:00.061Z","studySha256":"707a61e1a7ebb83849e38769e3d239ffd45eabd911d3b23a1f62efe72500a500","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-17","leadSponsor":"Shanghai Bovax Biotechnology Co., Ltd.","collaboratorCount":0,"minimumAge":"9 Years","maximumAge":"45 Years","sex":"ALL","healthyVolunteers":true,"hasEligibility":true,"enrolment":330,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-01-15","startedType":"actual","enrolled":330,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06756269/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/"}]}}